

References

I-211

1. Givlaari (givosiran), injection, for subcutaneous use [package insert]. Alnylam Pharmaceuticals, Inc. Cambridge, MA. 2019. Revised 01/2022.
2. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Givosiran.
3. Micromedex DrugDex Compendium®. 2022. Givosiran.
4. Sardh E, Harper P, Balwani M, et al. Phase 1 Trial of an RNA interference therapy for acute intermittent porphyria. *NEJM*. 2019; 380:549-558.
5. Gouya L, Sardh E, Balwani M, et al. ENVISION, A phase 3 study to evaluate the efficacy and safety of givosiran, an investigational RNAi therapeutic safety of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1, in acute hepatic porphyria patients. *Hepatology*. 70(1).e81-e82.
6. Balwani M, Sardh E, Ventura P, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. *N Engl J Med*. 2020;382(24):2289-2301.
7. Givosiran Sodium In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated January 13, 2020.
8. Ventura P, Bonkovsky HL, Gouya L, et al. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. *Liver Int*. 2022;42:161-172.